Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 81

1.

An uphill battle downstream of RAF.

Collisson EA.

J Clin Oncol. 2011 Jun 10;29(17):2298-300. doi: 10.1200/JCO.2011.34.9316. Epub 2011 Apr 25. No abstract available.

PMID:
21519020
[PubMed - indexed for MEDLINE]
Free Article
2.

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA.

J Clin Oncol. 2011 Jun 10;29(17):2357-63. doi: 10.1200/JCO.2010.33.9473. Epub 2011 Apr 25.

PMID:
21519026
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS, Malek S.

Nature. 2010 Mar 18;464(7287):431-5. doi: 10.1038/nature08833. Epub 2010 Feb 3.

PMID:
20130576
[PubMed - indexed for MEDLINE]
4.

Hepatocellular carcinoma with persistent hepatitis B virus infection shows unusual downregulation of Ras expression and differential response to Ras mediated signaling.

Bose S, Sakhuja P, Bezawada L, Agarwal AK, Kazim SN, Khan LA, Sarin SK, Ramakrishna G.

J Gastroenterol Hepatol. 2011 Jan;26(1):135-44. doi: 10.1111/j.1440-1746.2010.06305.x.

PMID:
21175807
[PubMed - indexed for MEDLINE]
6.

KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer.

Nakayama N, Nakayama K, Yeasmin S, Ishibashi M, Katagiri A, Iida K, Fukumoto M, Miyazaki K.

Br J Cancer. 2008 Dec 16;99(12):2020-8. doi: 10.1038/sj.bjc.6604783. Epub 2008 Nov 18.

PMID:
19018267
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Therapeutic targets in melanoma: map kinase pathway.

Haluska FG, Ibrahim N.

Curr Oncol Rep. 2006 Sep;8(5):400-5. Review.

PMID:
16901402
[PubMed - indexed for MEDLINE]
8.

From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS.

Vauthey JN, Kopetz SE.

Cancer. 2013 Dec 1;119(23):4083-5. doi: 10.1002/cncr.28348. Epub 2013 Sep 19. No abstract available.

PMID:
24105015
[PubMed - indexed for MEDLINE]
9.

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia.

Case M, Matheson E, Minto L, Hassan R, Harrison CJ, Bown N, Bailey S, Vormoor J, Hall AG, Irving JA.

Cancer Res. 2008 Aug 15;68(16):6803-9. doi: 10.1158/0008-5472.CAN-08-0101.

PMID:
18701506
[PubMed - indexed for MEDLINE]
Free Article
10.

A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.

Scholtka B, Schneider M, Melcher R, Katzenberger T, Friedrich D, Berghof-J├Ąger K, Scheppach W, Steinberg P.

Cancer Epidemiol. 2009 Aug;33(2):123-9. doi: 10.1016/j.canep.2009.05.001. Epub 2009 Jun 10.

PMID:
19679059
[PubMed - indexed for MEDLINE]
11.

Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101.

Chiorean EG, Ramasubbaiah R, Yu M, Picus J, Bufill JA, Tong Y, Coleman N, Johnston EL, Currie C, Loehrer PJ.

Oncologist. 2012;17(1):13. doi: 10.1634/theoncologist.2011-0253. Epub 2011 Dec 30.

PMID:
22210086
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway.

Wong KK.

Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):28-35. Review.

PMID:
19149686
[PubMed - indexed for MEDLINE]
13.

[Gene mutation (KRAS, BRAF, PIK3CA) and clinical benefit of anti-EGFR antibody].

Ueno T, Moriwaki T, Hyodo I.

Nihon Rinsho. 2011 Apr;69 Suppl 3:477-81. Review. Japanese. No abstract available.

PMID:
22214007
[PubMed - indexed for MEDLINE]
14.

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic.

Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL.

J Clin Invest. 2008 Nov;118(11):3651-9. doi: 10.1172/JCI35437. Epub 2008 Oct 23.

PMID:
18949058
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Impact of KRAS and BRAF gene mutations on targeted therapies in colorectal cancer.

Bass A.

J Clin Oncol. 2011 Jul 1;29(19):2728-9. doi: 10.1200/JCO.2011.36.1816. Epub 2011 Jun 6. No abstract available.

PMID:
21646605
[PubMed - indexed for MEDLINE]
Free Article
16.

Drug discovery: How melanomas bypass new therapy.

Solit D, Sawyers CL.

Nature. 2010 Dec 16;468(7326):902-3. doi: 10.1038/468902a. No abstract available.

PMID:
21164474
[PubMed - indexed for MEDLINE]
17.

Sorafenib in liver cancer--just the beginning.

Roberts LR.

N Engl J Med. 2008 Jul 24;359(4):420-2. doi: 10.1056/NEJMe0802241. No abstract available.

PMID:
18650519
[PubMed - indexed for MEDLINE]
18.

KRAS and BRAF mutation status in patients with sporadic colorectal cancer: data from two different Mediterranean countries.

Symvoulakis EK, Zaravinos A, Zoras O, Spandidos DA.

Int J Biol Markers. 2011 Oct-Dec;26(4):276-7. doi: 10.5301/JBM.2011.8874. No abstract available.

PMID:
22139644
[PubMed - indexed for MEDLINE]
19.

Colorectal cancer: cetuximab, KRAS, BRAF, PIK3CA mutations and beyond.

Katsios C, Ziogas DE, Roukos DH.

Expert Rev Gastroenterol Hepatol. 2010 Oct;4(5):525-9. doi: 10.1586/egh.10.62. No abstract available.

PMID:
20932136
[PubMed - indexed for MEDLINE]
20.

Manumycin inhibits cell proliferation and the Ras signal transduction pathway in human hepatocellular carcinoma cells.

Zhou JM, Zhu XF, Pan QC, Liao DF, Li ZM, Liu ZC.

Int J Mol Med. 2003 Jun;11(6):767-71.

PMID:
12736720
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk